Enhanced anabolic cytokine production and delivery system

Patent metadata

Field	Value
Publication number	US-9241977-B2
Application number	US-201414188899-A
Country	US
Kind code	B2
Filing date	Feb 25, 2014
Priority date	Mar 1, 2013
Publication date	Jan 26, 2016
Grant date	Jan 26, 2016

Abstract

Techniques and devices for removing (filtering out) unwanted/inhibitory components (for example, products, byproducts and/or cell output such as inhibitory catabolic proteins) from a composition (for example, autologous fluid or serum) containing such unwanted/inhibitory components. The devices include at least one construct designed to contain a composition (for example, autologous fluid or serum) containing inhibitory/unwanted components (products, byproducts and/or output of cells such as inhibitory catabolic proteins). The construct is provided with interior walls including specific protein capturing means designed to remove the inhibitory/unwanted component(s) (for example, specific protein(s)) from the composition. Proteins targeted for capture include, but are not limited to, catabolic cytokines such as IL-1β, IL-α, IL-6, TNFα, IFNγ and MMPS as these proteins inhibit the healing process.

First claim

What is claimed is:

1. A method for selectively removing unwanted components from serum or autologous fluid, comprising:
incubating the serum or autologous fluid in a construct having an internal construct wall that is coated with at least one protein binding site or passing the serum or autologous fluid through a construct having an internal construct wall that is coated with at least one protein binding site, wherein the at least one protein binding site binds a catabolic cytokine, wherein a IL-1Ra/IL-1β ratio of the serum or autologous fluid is about four times greater after the serum or autologous fluid contacts the protein binding site; and
removing the serum or autologous fluid from the construct.

2. The method of claim 1 , wherein the construct is a vial or syringe.

3. The method of claim 1 , wherein the construct is tubing with two open ends.

4. The method of claim 1 , wherein the internal construct wall comprises a formation that enlarges surface area.

5. The method of claim 4 , wherein the formation comprises a ribbed area that is coated with the at least one protein binding site.

6. The method of claim 1 , further comprising injecting the removed serum or autologous fluid into a mammal to promote tissue growth.

7. The method of claim 1 , wherein the catabolic cytokine is selected from the group consisting of IL-1β, IL-α, IL-6, TNFα, IFNγ and matrix metalloproteinases.

8. The method of claim 6 , wherein the injection is into damaged tissue of the mammal.

9. The method of claim 8 , wherein the damaged tissue is a joint, a nerve root or a damaged tendon.

10. The method of claim 1 , wherein the catabolic cytokine is IL-1β.

11. The method of claim 1 , wherein the protein binding site binds IL-1β.

12. The method of claim 11 , wherein the protein binding site comprises an anti-IL-1β antibody.

13. The method of claim 1 , wherein the protein binding site comprises a capture antibody.

14. A method for selectively removing unwanted components from serum or autologous fluid, comprising:
incubating the serum or autologous fluid in tubing with two open ends having internal tubing walls coated with at least one protein binding site, or passing the serum or autologous fluid through tubing having internal tubing walls coated with the at least one protein binding site, wherein the at least one protein binding site binds a catabolic cytokine, wherein an IL-1Ra/IL-1β ratio of the serum or autologous fluid is about four times greater after the serum or autologous fluid contacts the at least one protein binding site, wherein the serum or autologous fluid passes back and forth through the tubing; and
removing the serum or autologous fluid from the tubing.

15. The method of claim 14 , further comprising injecting the removed serum or autologous fluid into a mammal to promote tissue growth.

16. The method of claim 15 , wherein the injection is into damaged tissue of the mammal.

17. The method of claim 16 , wherein the damaged tissue is a joint, a nerve root or a damaged tendon.

18. The method of claim 14 , wherein the internal tubing walls comprise a formation that enlarges surface area.

19. The method of claim 15 , wherein the formation comprises a ribbed area that is coated with the at least one protein binding site.

20. The method of claim 14 , wherein the catabolic cytokine is selected from the group consisting of IL-β, IL-α, IL-6, TNFα, IFNγ, and matrix metalloproteinases.

21. The method of claim 14 , wherein the catabolic cytokine is IL-1β.

22. The method of claim 14 , wherein the at least one protein binding site binds IL-1β.

23. The method of claim 22 , wherein the at least one protein binding site comprises an anti-IL-1β antibody.

24. The method of claim 14 , wherein the at least one protein binding site comprises a capture antibody.

Assignees

• Arthrex Inc

Inventors

• Bare Christopher M
• Roller Brandon L
• Tucker Melissa S

Classifications

• A61K35/16 Primary

  Blood plasma; Blood serum (umbilical cord blood A61K35/51) · CPC title

• A61J1/2089

  Containers or vials which are to be joined to each other in order to mix their contents (combinations of vial and syringe for mixing their contents A61J1/2096) · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61K38/1793 Primary

  for cytokines; for lymphokines; for interferons · CPC title

• C07K16/245

  IL-1 · CPC title